Phase 3 Study of BGB-A317 Versus Sorafenib in Patients With Unresectable HCC
about
Phase 3 Study of BGB-A317 Versus Sorafenib in Patients With Unresectable HCC
description
clinical trial
@en
klinisch onderzoek
@nl
name
Phase 3 Study of BGB-A317 Versus Sorafenib in Patients With Unresectable HCC
@en
type
label
Phase 3 Study of BGB-A317 Versus Sorafenib in Patients With Unresectable HCC
@en
prefLabel
Phase 3 Study of BGB-A317 Versus Sorafenib in Patients With Unresectable HCC
@en
P17
P6153
P1050
P1476
RATIONALE-301: A Randomized, O ...... table Hepatocellular Carcinoma
@en
P3098
NCT03412773
P4844
P580
2017-12-28T00:00:00Z
P582
2022-01-01T00:00:00Z